title: Using Simulation Modeling to Inform Strategies to Reduce Breast Cancer Mortality in Black Women in the District of Columbia.
abstract: BACKGROUND
  Black women in the District of Columbia (DC) have the highest breast cancer mortality in the US. Local cancer control planners are interested in how to most efficiently reduce this mortality.
  
  
  METHODS
  An established simulation model was adapted to reflect the experiences of Black women in DC and estimate the past and future impact of changes in use of screening and adjuvant treatment.
  
  
  RESULTS
  The model estimates that the observed reduction in mortality that occurred from 1975 to 2007 attributable to screening, treatment, and both was 20.2%, 25.7%, and 41.0% respectively. The results suggest that, by 2020, breast cancer mortality among Black women in DC could be reduced by 6% more by initiating screening at age 40 vs. age 50. Screening annually may also reduce mortality to a greater extent than biennially, albeit with a marked increase in false positive screening rates.
  
  
  CONCLUSIONS
  This study demonstrates how modeling can provide data to assist local planners as they consider different cancer control policies based on their individual populations.
authors.affiliation: Department of Oncology, Georgetown University Medical Center and Cancer Control Program, Lombardi Comprehensive Cancer Center, 3300 Whitehaven St, NW, Suite 4100, Washington, DC 20007.
authors.forename: Aimee M
authors.initials: AM
authors.lastname: Near
authors.forename: Jeanne S
authors.initials: JS
authors.lastname: Mandelblatt
authors.forename: Clyde B
authors.initials: CB
authors.lastname: Schechter
authors.forename: Michael A
authors.initials: MA
authors.lastname: Stoto
references.citation: AJR Am J Roentgenol. 1997 Oct;169(4):1001-8
references.pmid: 9308451
references.citation: J Natl Cancer Inst Monogr. 2006;(36):37-47
references.pmid: 17032893
references.citation: J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92
references.pmid: 19571256
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Ann Intern Med. 2009 Nov 17;151(10):738-47
references.pmid: 19920274
references.citation: Cancer Causes Control. 2005 Aug;16(6):701-12
references.pmid: 16049809
references.citation: Eur J Cancer. 1995;31A(3):348-53
references.pmid: 7786600
references.citation: J Natl Cancer Inst Monogr. 2006;(36):47-55
references.pmid: 17032894
references.citation: Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):112-22
references.pmid: 21119071
references.citation: Lancet. 1998 Sep 19;352(9132):930-42
references.pmid: 9752815
references.citation: Aust J Public Health. 1993 Mar;17(1):42-50
references.pmid: 8357894
references.citation: J Med Screen. 1999;6(1):30-4
references.pmid: 10321368
references.citation: J Natl Cancer Inst. 2002 Nov 6;94(21):1626-34
references.pmid: 12419789
references.citation: J Natl Cancer Inst Monogr. 2006;(36):19-25
references.pmid: 17032890
references.citation: Ann Intern Med. 2009 Nov 17;151(10):716-26, W-236
references.pmid: 19920272
references.citation: J Natl Cancer Inst Monogr. 2001;(30):36-43
references.pmid: 11773290
references.citation: Lancet. 1998 May 16;351(9114):1451-67
references.pmid: 9605801
references.citation: J Natl Cancer Inst Monogr. 2006;(36):26-9
references.pmid: 17032891
references.citation: J Natl Cancer Inst Monogr. 2006;(36):7-15
references.pmid: 17032888
references.citation: Cancer. 2004 Jan 1;100(1):139-48
references.pmid: 14692034
references.citation: Cancer Causes Control. 2000 Sep;11(8):697-705
references.pmid: 11065006